Hemolytic Transfusion Reactions.
Panch SR, Montemayor-Garcia C, Klein HG.
N Engl J Med. 2019 Jul 11;381(2):150-162. doi: 10.1056/NEJMra1802338.
Noninfectious transfusion-associated adverse events and their mitigation strategies.
Goel R, Tobian AAR, Shaz BH.
Blood. 2019 Apr 25;133(17):1831-1839. doi: 10.1182/blood-2018-10-833988. Epub 2019 Feb 26.
Does ABO and RhD matching matter for platelet transfusion?
Dunbar NM.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):512-517. doi: 10.1182/hematology.2020000135.
Hemolysis from ABO Incompatibility.
Simmons DP, Savage WJ.
Hematol Oncol Clin North Am. 2015 Jun;29(3):429-43. doi: 10.1016/j.hoc.2015.01.003. Epub 2015 Mar 10.
Hemolytic Disease of Newborn: Beyond Rh-D and ABO Incompatibility.
Karanam A, Bandiya P.
Indian Pediatr. 2021 Aug 15;58(8):794-795.
The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility.
Lozano M, Cid J.
Transfus Med Rev. 2003 Jan;17(1):57-68. doi: 10.1053/tmrv.2003.50003.
Immunohematologic diseases.
Zweiman B, Patten E.
JAMA. 1982 Nov 26;248(20):2677-82.
Pathobiology of transfusion reactions.
Zimring JC, Spitalnik SL.
Annu Rev Pathol. 2015;10:83-110. doi: 10.1146/annurev-pathol-012414-040318.
Blood product transfusions and reactions.
Osterman JL, Arora S.
Emerg Med Clin North Am. 2014 Aug;32(3):727-38. doi: 10.1016/j.emc.2014.04.012. Epub 2014 Jun 12.
Preventing incompatible transfusions.
Contreras M, de Silva M.
BMJ. 1994 May 7;308(6938):1180-1. doi: 10.1136/bmj.308.6938.1180.
